EpiCast Report: Colorectal Cancer Epidemiology Forecast to 2022




$ 3995

In Stock

EpiCast Report: Colorectal Cancer Epidemiology Forecast to 2022


Colorectal cancer is the third most common cancer in men and second most common cancer in women. GlobalDatas epidemiologists expect the number of incident and prevalent cases of colorectal cancer in the US, Germany, Italy, Spain, the UK, Japan, India, and China to increase during the forecast period. Incident and prevalent cases in France is expected to stay relatively constant. The number of total incident cases for all markets combined will increase from 1.23 million cases in 2012 to 1.75 million cases in 2022 at the rate of 4.22% per year. China has the largest number of incident cases in 2012 (645,057 cases), in 2022 (1.05 million cases), as well as the highest growth (6.32% per year) of all nine markets. The markets vary in age distribution of incident cases, gender gap, cancer stage at diagnosis, and screening programs. However, resection treatment is universally common where around 70-90% of colorectal cases in each market receive resection treatment.


  • Provides an overview of risk factors and global trends for colorectal cancer in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) along with emerging markets India and China. 
  • Includes a 10-year epidemiological forecast of incident and five-year prevalent cases of colorectal cancer. 
  • Describes patient population through segmentation by gender, age, stage at diagnosis (TNM/AJCC I-IV), and resection treatment status.

Reasons to buy

  • Develop business strategies by understanding the trends that shape and drive the global colorectal cancer market. 
  • Quantify patient populations in the global colorectal cancer market to improve product development, pricing, and launch plans. 
  • Organize sales and marketing efforts by identifying the age groups, gender, stages of diagnosis, and resection-treated populations that present the best opportunities for colorectal cancer therapeutics in the nine major markets.
Table of Contents

1 Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 5

2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 6
2.3 Upcoming Reports 6

3 Epidemiology 7
3.1 Risk Factors and Comorbidities 7
3.1.1 The risk of Developing Colorectal Cancer Increases with Age 7
3.1.2 Early Screening Programs Detect Precancerous Polyps and Reduce Mortality 7
3.1.3 People with a First-Degree Family Member Diagnosed with Colorectal Cancer are Almost Five Times as Likely to Develop the Disease 8
3.1.4 Chronic Inflammatory Bowel Disease Increases Risk up to 20 Times 8
3.2 Global and Historical Trends 9
3.2.1 United States 9
3.2.2 France 10
3.2.3 Germany 10
3.2.4 Italy 11
3.2.5 Spain 11
3.2.6 United Kingdom 12
3.2.7 Asia 12
3.3 Forecast Methodology 13
3.3.1 Sources Used 14
3.3.2 Sources Not Used 16
3.3.3 Forecast Methods and Assumptions, Incident Cases 17
3.3.4 Forecast Methods and Assumptions, Prevalent Cases 18
3.4 Epidemiology Forecast (20122022) 18
3.4.1 Total Incident Cases of Colorectal Cancer 18
3.4.2 Age-Specific Incident Cases of Colorectal Cancer 20
3.4.3 Gender-Specific Incident Cases of Colorectal Cancer 21
3.4.4 Age-Standardized Incidence 23
3.4.5 Segmentation of Incident Cases 24
3.4.6 Patients Undergoing Resection 25
3.4.7 Five-Year Prevalent Cases of Colorectal Cancer 26
3.5 Discussion 27

4 Appendix 30
4.1 Bibliography 30
4.2 About the Authors 36
4.2.1 Epidemiologists 36
4.2.2 Reviewers 37
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 38
4.2.4 Global Head of Healthcare 38
4.3 About GlobalData 39
4.4 About EpiCast 39
4.5 Contact Us 40
4.6 Disclaimer 40

Table 1: Risk Factors and Comorbidities for Colorectal Cancer 7
Table 2: 9MM, Sources of Colorectal Cancer Incidence Data 14
Table 3: 9MM, Incident Cases of Colorectal Cancer, Ages
Figure 1: 9MM, Incident Cases of Colorectal Cancer, Ages